Highlights Newron Pharmaceuticals S.p.A.

Equities

NWRN

IT0004147952

Market Closed - Swiss Exchange Other stock markets 09:01:47 25/06/2024 pm IST			5-day change	1st Jan Change
9.56 ^CHF	-12.77%		-9.98%	+93.13%

13/05	Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients	CI
30/04	Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Newron Pharmaceuticals S.P.A Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients	13/05	CI
Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	30/04	CI
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
Newron Pharmaceuticals' FY23 Loss Narrows; Revenue Up	19/03	MT
Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia	04/01	CI
Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide	29/12	CI
Newron Pharmaceuticals Completes Enrolment of Schizophrenia Patients for Evenamide Clinical Study	29/12	MT
Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia	09/23/09	CI
Newron Pharmaceuticals Net Loss Narrows in H1; Revenue Grows	04/23/04	MT
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	04/23/04	CI
Newron Pharmaceuticals S.p.A. Presents Six-Month Interim Data from the First 100 Patients Randomized in Study 014/015 At the 31St European Congress of Psychiatry	28/23/28	CI
Newron Pharmaceuticals S.p.A. Reports Compelling Topline Results from All Patients in Study 014, its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia	20/23/20	CI
Newron Pharmaceuticals' Net Loss Widens in FY22	14/23/14	MT
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Newron Reports Striking One-Year Interim Efficacy Results from Its Phase Ii Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia	16/23/16	CI
Newron Pharmaceuticals S.p.A. Announces Striking Six-Month Interim Results from Its Exploratory Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia	03/23/03	CI
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	15/22/15	CI
Newron Pharmaceuticals's H1 Loss Narrows as Revenue Inches Up	15/22/15	MT
Newron Pharmaceuticals S.P.A. Presents Encouraging Interim Results for Evenamide in Patients with Treatment-Resistant Schizophrenia At the 33Rd Cinp Hybrid World Congress of Neuropsychopharmacology	07/22/07	CI
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021	16/22/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Newron Pharmaceuticals S.p.A.

Equities

NWRN

IT0004147952

Highlights

Filters